FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

2010 • 2,249 citations

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

2013 • 2,055 citations

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 • 1,732 citations

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

2014 • 1,587 citations

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

2008 • 1,585 citations

Detection and quantification of mutations in the plasma of patients with colorectal tumors

2005 • 1,118 citations

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

2003 • 808 citations

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 • 745 citations

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

2015 • 715 citations

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

2014 • 602 citations

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

2014 • 477 citations

Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients

2008 • 217 citations

Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy

2014 • 144 citations

Calgb/Swog 80405: Phase III Trial of Irinotecan/5-Fu/Leucovorin (Folfiri) or Oxaliplatin/5-Fu/Leucovorin (Mfolfox6) with Bevacizumab (Bv) or Cetuximab (Cet) for Patients (Pts) with Expanded Ras Analyses Untreated Metastatic Adenocarcinoma of the Colon Or Rectum (Mcrc)

2014 • 107 citations

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer

2013 • 100 citations

Rapid Detection of K-ras Mutations in Bile by Peptide Nucleic Acid-mediated PCR Clamping and Melting Curve Analysis: Comparison with Restriction Fragment Length Polymorphism Analysis

2004 • 68 citations

Personalized cancer treatment and the myth of KRAS wild-type colon tumors.

2013 • 40 citations

Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management

2014 • 1 citations